Re-stenosis After Drug-eluting Stents in Cardiac Allograft Vasculopathy

Raed A. Aqel, Bryan J. Wells, Fadi G. Hage, Jose Tallaj, Raymond Benza, Salpy Pamboukian, Barry Rayburn, David McGiffin, James Kirklin, Robert Bourge

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)


Background: Cardiac allograft vasculopathy (CAV) constitutes a primary cause of death after heart transplantation. Balloon angioplasty and bare metal stents have been used for revascularization but they are associated with a high risk of re-stenosis. Limited data have shown favorable results with drug-eluting stents (DES). This study examines the rate of re-stenosis for DES in CAV as well as predictors for its occurrence. Methods: Cardiac transplant patients who received at least one DES for a previously untreated coronary lesion were included. These patients were retrospectively followed until February 2007. Re-stenosis was defined as ≥50% lumen diameter narrowing on coronary angiography at the site of the DES. Results: During the study period, 35 patients underwent percutaneous coronary intervention (PCI) on a total of 84 de novo lesions. The mean follow-up was 22 ± 14 months. Twenty-six (31%) lesions developed re-stenosis during follow-up. Re-stenosis rates were 18%, 21% and 26% at 6, 9 and 12 months, respectively. Predictors of re-stenosis included non-white race, ischemic etiology, intervention precipitated by symptoms and severe stenosis (≥90% stenosis) of the target lesion. Conclusions: Use of DES has a favorable outcome when used in heart transplant patients for the treatment of CAV. An aggressive strategy for the treatment of CAV using DES may provide good long-term outcome compared with other available therapies.

Original languageEnglish
Pages (from-to)610-615
Number of pages6
JournalThe Journal of Heart and Lung Transplantation
Issue number6
Publication statusPublished - 1 Jun 2008
Externally publishedYes

Cite this